Table 1_The impact of comorbidities on surgical outcome and mortality in minimally invasive mitral valve surgery: a systematic review.docx by Vanessa I. T. Zwaans (22163257)

“…Left atrial (LA) diameter decreased significantly from 50.37 mm preoperatively to 40.41%mm postoperatively (p < 0.001), LVDD was significantly reduced after MIMVS (p < 0.001). …”

Supplementary Material for: Camrelizumab combined with Lenvatinib and RALOX-HAIC for unresectable hepatocellular carcinoma (Cal Era): a prospective, single-arm, phase II trial by figshare admin karger (2628495)

“…Furthermore, risk stratification based on these three biomarkers revealed shorter progression-free survival and overall survival in high-risk versus low-risk subgroups (P < 0.05). …”

Table1_Adverse event profile differences between pralsetinib and selpercatinib: a real-world study based on the FDA adverse events reporting system.docx by Qiong Jie (13270095)

“…Unexpected AEs such as rhabdomyolysis, myocardial injury and cognitive disorder were associated with pralsetinib, while selpercatinib was linked with pulmonary embolism, deep vein thrombosis, and pericardial effusion. The risk of AEs such as decreased platelet count, anemia, decreased white blood cell count, pneumonitis, asthenia, and edema caused by pralsetinib is significantly higher than that of selpercatinib. …”

Image2_Adverse event profile differences between pralsetinib and selpercatinib: a real-world study based on the FDA adverse events reporting system.TIF by Qiong Jie (13270095)

“…Unexpected AEs such as rhabdomyolysis, myocardial injury and cognitive disorder were associated with pralsetinib, while selpercatinib was linked with pulmonary embolism, deep vein thrombosis, and pericardial effusion. The risk of AEs such as decreased platelet count, anemia, decreased white blood cell count, pneumonitis, asthenia, and edema caused by pralsetinib is significantly higher than that of selpercatinib. …”

Table2_Adverse event profile differences between pralsetinib and selpercatinib: a real-world study based on the FDA adverse events reporting system.docx by Qiong Jie (13270095)

“…Unexpected AEs such as rhabdomyolysis, myocardial injury and cognitive disorder were associated with pralsetinib, while selpercatinib was linked with pulmonary embolism, deep vein thrombosis, and pericardial effusion. The risk of AEs such as decreased platelet count, anemia, decreased white blood cell count, pneumonitis, asthenia, and edema caused by pralsetinib is significantly higher than that of selpercatinib. …”

Image1_Adverse event profile differences between pralsetinib and selpercatinib: a real-world study based on the FDA adverse events reporting system.TIF by Qiong Jie (13270095)

“…Unexpected AEs such as rhabdomyolysis, myocardial injury and cognitive disorder were associated with pralsetinib, while selpercatinib was linked with pulmonary embolism, deep vein thrombosis, and pericardial effusion. The risk of AEs such as decreased platelet count, anemia, decreased white blood cell count, pneumonitis, asthenia, and edema caused by pralsetinib is significantly higher than that of selpercatinib. …”

Data Sheet 1_Global, regional, and national burden of ischemic heart disease attributed to non-optimal temperature, 1990–2021: an age-period-cohort analysis of the global burden of... by Xiaoqing Xia (14607269)

“…Background<p>In recent years, non-optimal temperature has significantly impacted global health including ischemic heart disease (IHD).…”

Clozapine for persons with neurodevelopmental disorders: a systematic review and expert recommendations for clinical practice by Hélène Verdoux (110251)

“…After clozapine initiation, a decreased frequency of challenging behavior persisting over time was reported in most participants included in clinical studies, and a significant reduction in the number of admissions in the population-based two-year mirror-image study. …”

Scatterplot 8. by Chao Yang (174810)

“…When the HAR was lower than 0.13, mortality within 28 days after ICU admission decreased significantly as the HAR increased. When the HAR was higher than 0.13, the HAR was not a protective factor for mortality within 28 days after ICU admission. …”

Scatterplot 5. by Chao Yang (174810)

“…When the HAR was lower than 0.13, mortality within 28 days after ICU admission decreased significantly as the HAR increased. When the HAR was higher than 0.13, the HAR was not a protective factor for mortality within 28 days after ICU admission. …”

Scatterplot 9. by Chao Yang (174810)

“…When the HAR was lower than 0.13, mortality within 28 days after ICU admission decreased significantly as the HAR increased. When the HAR was higher than 0.13, the HAR was not a protective factor for mortality within 28 days after ICU admission. …”

Image 2_The association between fluid balance trajectories and prognosis in ICU patients with cardiac arrest, a group-based trajectory model analysis.tiff by Qitian Zhang (19791372)

“…Kaplan–Meier survival analysis showed that the survival rate in Trajectory 1 was significantly higher than in the other trajectory groups, with the fluid overload group exhibiting a notably higher mortality risk than the non-overload group. …”

Scatterplot 1. by Chao Yang (174810)

“…When the HAR was lower than 0.13, mortality within 28 days after ICU admission decreased significantly as the HAR increased. When the HAR was higher than 0.13, the HAR was not a protective factor for mortality within 28 days after ICU admission. …”

Table 1_The association between fluid balance trajectories and prognosis in ICU patients with cardiac arrest, a group-based trajectory model analysis.xlsx by Qitian Zhang (19791372)

“…Kaplan–Meier survival analysis showed that the survival rate in Trajectory 1 was significantly higher than in the other trajectory groups, with the fluid overload group exhibiting a notably higher mortality risk than the non-overload group. …”

Scatterplot 6. by Chao Yang (174810)

“…When the HAR was lower than 0.13, mortality within 28 days after ICU admission decreased significantly as the HAR increased. When the HAR was higher than 0.13, the HAR was not a protective factor for mortality within 28 days after ICU admission. …”

Scatterplot 2. by Chao Yang (174810)

“…When the HAR was lower than 0.13, mortality within 28 days after ICU admission decreased significantly as the HAR increased. When the HAR was higher than 0.13, the HAR was not a protective factor for mortality within 28 days after ICU admission. …”

Raw data of this study. by Chao Yang (174810)

“…When the HAR was lower than 0.13, mortality within 28 days after ICU admission decreased significantly as the HAR increased. When the HAR was higher than 0.13, the HAR was not a protective factor for mortality within 28 days after ICU admission. …”

Image 1_The association between fluid balance trajectories and prognosis in ICU patients with cardiac arrest, a group-based trajectory model analysis.tiff by Qitian Zhang (19791372)

“…Kaplan–Meier survival analysis showed that the survival rate in Trajectory 1 was significantly higher than in the other trajectory groups, with the fluid overload group exhibiting a notably higher mortality risk than the non-overload group. …”

Scatterplot 4. by Chao Yang (174810)

“…When the HAR was lower than 0.13, mortality within 28 days after ICU admission decreased significantly as the HAR increased. When the HAR was higher than 0.13, the HAR was not a protective factor for mortality within 28 days after ICU admission. …”

Scatterplot 3. by Chao Yang (174810)

“…When the HAR was lower than 0.13, mortality within 28 days after ICU admission decreased significantly as the HAR increased. When the HAR was higher than 0.13, the HAR was not a protective factor for mortality within 28 days after ICU admission. …”